Modus Therapeutics Holding AB (publ)

DB:99Z Stock Report

Market Cap: €4.0m

Modus Therapeutics Holding Future Growth

Future criteria checks 0/6

Modus Therapeutics Holding's earnings are forecast to decline at 44.9% per annum. EPS is expected to decline by 43% per annum.

Key information

-44.9%

Earnings growth rate

-43.0%

EPS growth rate

Biotechs earnings growth42.4%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

Low

Last updated20 Nov 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:99Z - Analysts future estimates and past financials data (SEK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/2024N/A-15-14-14N/A
6/30/2024N/A-15-13-13N/A
3/31/2024N/A-15-14-14N/A
12/31/2023N/A-18-17-17N/A
9/30/2023N/A-23-22-22N/A
6/30/2023N/A-23-22-22N/A
3/31/2023N/A-21-21-21N/A
12/31/2022N/A-18-22-22N/A
9/30/2022N/A-21-22-22N/A
6/30/2022N/A-23-23-23N/A
3/31/2022N/A-22-22-22N/A
12/31/2021N/A-21-16-16N/A
9/30/2021N/A-9-9-9N/A
6/30/2021N/A-6-6-6N/A
3/31/2021N/A-5-5-5N/A
12/31/2020N/A-6-7-7N/A
12/31/2019N/A-44-48-48N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 99Z is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 99Z is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 99Z is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if 99Z's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if 99Z's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 99Z's Return on Equity is forecast to be high in 3 years time


Discover growth companies